SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S42 - Update in Muscular Dystrophy

Event Time: Thursday April 27, 2017 1:00 pm to 3:00 pm
Topic(s): Neuromuscular and Clinical Neurophysiology (EMG)
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
2:35 PM - 3:00 PM Discussion Matthew Wicklund MD, FAAN 

Disclosures

Speaker Disclosure
Matthew P. Wicklund, MD, FAAN Dr. Wicklund has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme. Dr. Wicklund has received research support from Marathon, Sarepta Therapeutics, and Sanofi-Genzyme.

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Eteplirsen for the Treatment of Duchenne Muscular Dystrophy (DMD) JS Charleston
Disclosure:
Dr. Charleston has received personal compensation for activities with Sarepta Therapeutics as an employee.

1:12 PM 002 Genetic landscape of Limb-Girdle Muscular Dystrophies from a Large Cohort of Neuromuscular Disease Patients Samya Chakravorty
Disclosure:
Dr. Chakravorty has nothing to disclose.

1:24 PM 003 Therapeutic Effect of KPT-350 in a Preclinical Model of Duchenne Muscular Dystrophy Devin Gibbs
Disclosure:
Dr. Alexander has nothing to disclose.

1:36 PM 004 Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) and Loss of Ambulation (LOA) JR Mendell
Disclosure:
Investigator for Sarepta Therapeutics, Inc. clinical trial(s) Attended global advisory board for Sarepta Therapeutics, Inc..

1:48 PM 005 Genetic markers of myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) in human urine Layal Antoury
Disclosure:
Dr. Antoury has nothing to disclose.

2:00 PM 006 Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 distal and proximal muscles Giovanni Meola, MD, FAAN
Disclosure:
Dr. Meola has nothing to disclose.

2:12 PM 007 Cardiac function in the dystroglycanopathies Julia Collison
Disclosure:
Dr. Collison has nothing to disclose.

2:24 PM 008 Development of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Treatment of Duchenne Muscular Dystrophy (DMD) P Duda
Disclosure:
Dr. Frank has received personal compensation for activities with Sarepta Therapeutics, Inc. as an employee.

Register Now

Related Courses

Sunday April 22, 2018

7:00 AM-9:00 AM
C30 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies Michael Shy MD
1:00 PM-3:00 PM
C40 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies Michael Shy MD
1:00 PM-5:30 PM
C47 Neuromuscular Ultrasound Skills Workshop (Registration Required) Craig Zaidman MD
3:30 PM-5:30 PM
C54 Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing Michael Shy MD

Tuesday April 24, 2018

1:00 PM-5:30 PM
C118 EMG Skills Workshop: Basic Ezgi Tiryaki MD, FAAN

Wednesday April 25, 2018

7:00 AM-9:00 AM
C141 Mastering EMG Waveform Recognition Skills in Just Two Hours! Devon Rubin MD, FAAN
1:00 PM-3:00 PM
C154 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Christopher Gibbons MD, FAAN
3:30 PM-5:30 PM
C168 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System Christopher Gibbons MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C178 Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
1:00 PM-3:00 PM
C191 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Mark Bromberg MD, PhD, FAAN
3:30 PM-5:30 PM
C205 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
6:30 PM-9:30 PM
C209 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease Anne Connolly MD, FAAN

MEMBER LOG IN

Forgot Password?